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Abstract 
Objectives: To assess long term patient-reported swallow function following 
chemoradiotherapy for oropharyngeal carcinoma, and to evaluate the frequency of 
deterioration/improvement over years. 
 
Materials and Methods: 59 patients with oropharyngeal carcinoma treated with parotid-
sparing intensity modulated radiotherapy and concurrent chemotherapy between 2010-
2012 had previously completed the MD Anderson Dysphagia Inventory (MDADI) at a median 
of 34 months (range 24-59) post-treatment.  An MDADI was posted to 55 alive and disease-
free patients after a 30 month interval.  52/55 replies were received, median of 64 months 
(range 52-88) post-treatment.  27/52 (52%) had been managed with a prophylactic 
gastrostomy.  A 10-point or greater change of the MDADI scores was defined as clinically 
significant. 
 
Results: Overall in the whole cohort, patient reported swallow function showed a small 
absolute improvement in MDADI composite score  on the second MDADI questionnaire (>5 
years post-treatment) compared with the first MDADI (>2 years post-treatment), mean 68.0 
(SD 19.3) versus 64.0 (SD 16.3), p=0.021.Using the composite score, swallow function was 
stable over time in 29/52 (56%) of patients; a clinically significant improvement in swallow 
function over time was noted in 17/52 (33%) patients; conversely 6/52 (12%) of patients 
experienced a clinically significant deterioration with time.  Abnormality of pre-treatment 
diet and a prophylactic gastrostomy correlated with an inferior MDADI composite score on 
the later questionnaire (p=0.029 and p=0.044 respectively). 
 
Conclusions: Long term dysphagia is prevalent >5 years post-treatment.  Although long term 
swallow function is stable in the majority of patients, it is not static in a minority.  On MDADI 
composite summary scores 33% of patients experienced an improvement whilst 12% 
deteriorated with time. Further investigation is needed to determine underlying 
mechanisms behind these divergent outcomes. 
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Introduction 
 
Definitive (chemo)radiotherapy for head and neck cancer is a standard of care with the aim 
of locoregional tumour control with organ preservation.  Chemoradiotherapy can impair all 
phases of swallowing [1] and long term dysphagia is recognised as a major late toxicity [2-4].  
Dyphagia has been shown to have a major impact upon health-related quality-of-life (QoL) 
[5-8], and remains a priority concern for patients one year post treatment [5].  Early side 
effects impacting upon swallow function are well recognised may be attributed to mucositis 
and oedema; these improve gradually following completion of treatment. The pathogenesis 
of long term dysphagia is less well understood and is likely to relate to mechanisms 
including fibrosis, oedema, cranial neuropathy, trismus and osteoradionecrosis [2].  
Radiation-induced nerve and muscle dysfunction can develop slowly and may not be 
apparent for years following treatment [9].  
 
The majority of series examining dysphagia have focussed upon dysphagia occurring after 
only limited period of time post treatment (eg. 1-2 years) [5, 10-12].  Dysphagia over a much 
longer time period of >5 years post treatment is only occasionally reported [3, 13].  These 
data demonstrate that persistent dysphagia is prevalent; for example in a retrospective 
analysis of 78 patients with oropharyngeal carcinoma, 50% of patients had experienced a 
severe late dysphagia event after a median follow up of over 5 years [3]. 
 
A key issue is how often swallow function can be expected to improve, remain stable, 
deteriorate over multiple years following treatment.  There is very little data upon how 
dysphagia may change with increasing time from completion of treatment.  Hutcheson et al.  
[12] found a modest deterioration in swallow function 2 years post treatment compared 
with baseline in 47 patients using range of functional measures, with increased pharyngeal 
residue on videofluoroscopic swallowing study (VFSS).  Feng et al. [11] found that  VFSS 
measured swallow function did not change between 3 months and 2 years.  A retrospective 
study of 83 patients with median follow up of 3 years using the Sydney Swallow 
Questionnaire found no correlation between dysphagia severity and time from therapy [14].  
In a series of 39 patients assessed using the Australian Therapy Outcome Measures Frowen 
et al. [13] showed that patient-reported swallowing activity for solids significantly improved 
for all patients between 6 months and 5 years; however, by contrast the semi-solid 
swallowing measure deteriorated over time.   
 
The aim of the current study is to assess patient-reported swallow outcomes in the long 
term (>5 years) post-chemoradiotherapy for oropharyngeal carcinoma, and to evaluate 
changes with time following chemoradiotherapy, including determination of how commonly 
swallow function may improve/deteriorate.  We have previously evaluated patient reported 
swallow function at least 2 years post-chemoradiotherapy for oropharyngeal carcinoma 
using the MD Anderson Dysphagia Inventory (MDADI) [15] in a cohort of 59 patients with 
returned questionnaires [16]. The MDADI was re-administered to the same patients after a 
further 30 month interval (at least 4 ½ years post-chemoradiotherapy). 
 
Methods 
 
Study design 
The study was registered with the Institutional Quality Improvement Board.   
 
The aim of the study was to evaluate changes patient-reported swallow function at least 5 
years post-chemoradiotherapy using the MDADI tool in a cohort of patients who had 
previously completed the MDADI at least 2 years post-chemoradiotherapy.   
 
The MDADI is a validated reliable self-administered questionnaire which uses 20 questions 
ǁŚŝĐŚĂƌĞĚĞƐŝŐŶĞĚƚŽĂƐƐĞƐƐƉĂƚŝĞŶƚƐ ?ƉĞƌĐĞƉƚŝŽŶŽĨƚŚĞŝƌƐǁĂůůŽǁŝŶŐĂďŝůŝƚǇĂŶĚŚow this 
may impact upon their quality of life [15, 17].  Each question is scored on a 5-point scale 
ƌĂŶŐŝŶŐĨƌŽŵ ?ƐƚƌŽŶŐůǇĂŐƌĞĞ ?ƚŽ ?ƐƚƌŽŶŐůǇĚŝƐĂŐƌĞĞ ? ?YƵĞƐƚŝŽŶƐĂƌĞĚŝǀŝĚĞĚŝŶƚŽĞŵŽƚŝŽŶĂů ?
functional and physical subscales.  Two summary scores are obtained; the global scale is a 
single question scored individually and the composite is a score summarising the remaining 
19 questions.  Summary and subscale scores are normalised to a range from 20-100; a 
higher score indicates superior swallow-related quality of life/function. 
 
Patients were identified in a prior study in which patients were asked to compete the 
MDADI at least 2 years post-chemoradiotherapy [16].  In this prior study, patients with 
locally advanced squamous cell carcinoma of the oropharynx were identified who had 
received definitive concurrent chemoradiotherapy between October 2010-December 2012.  
Inclusion criteria were: oropharyngeal primary, squamous cell carcinoma, stage III/IV, non-
surgical treatment with curative intent, concurrent chemotherapy, IMRT including 
treatment of bilateral neck, disease free for at least 2 years following completion of 
radiotherapy.  Patients were excluded for recurrent disease, prior neck dissection, and for 
therapeutic enteral feeding prior to treatment.  As previously described [16], 94 patients 
were identified and exclusions were: 18 due to disease recurrence, 3 deaths without disease 
recurrence, 5 received therapeutic feeding pre-treatment.  The remaining 68 patients were 
posted the MDADI along with an explanatory letter in January 2014.  Completed MDADI 
forms were received from 59 (87%) of these patients.  Pre-treatment diet was categorized 
using prospectively collected pre-treatment dietitian and nursing assessments into: nil by 
mouth, sips, pureed, soft, normal. 
 
In this current study, electronic notes records were reviewed for the 59 patients who had 
returned a completed MDADI in the original study.  4 patients were excluded from being 
sent a further MDADI in the event of death or disease recurrence; 2 patients had died of 
unrelated causes, one patient was receiving chemotherapy for distant metastases and one 
patient had undergone salvage surgery for regional recurrence.   
The MDADI was sent with an explanatory letter to the remaining 55 patients in June 2017.  
All patients were a minimum 4 ½ years post-chemoradiotherapy and were disease free with 
no prior recurrence.  Completed MDADI questionnaires were received from 52 patients.  
 
Pre- and post-treatment support 
All patients routinely underwent dietetic, nursing and speech and language therapy (SLT) 
assessments pre-treatment.  During this period of time the institutional policy regarding a 
prophylactic or reactive approach to enteral nutritional support was to consider either a prophylactic 
gastrostomy or reactive nasogastric tube approach based upon clinician + patient preference. 
During treatment patients were routinely reviewed twice weekly by medical and nursing 
teams with additional dietetic and SLT input as required.  Post-treatment rehabilitation was 
offered to all patients in dedicated combined nursing, dietetic and SLT post-treatment 
clinics. 
 
Treatment details 
Induction chemotherapy 
Induction chemotherapy in this era was delivered to selected patients based upon clinician 
preference, patients and disease factors.  Induction chemotherapy constituted either TPF 
(docetaxel 75mg/m2, cisplatin 75mg/m2, 5-flurouracil (5-FU) 750mg/m2 days 2-5) [18] or PF 
(cisplatin 80mg/m2 and 5-FU 800mg/m2) [19]. 
 
Concurrent chemotherapy 
Standard concurrent chemotherapy was cisplatin 100mg/m2 days 1 and 29.  Carboplatin 
AUC4 was substituted in the event of a contraindication to cisplatin. 
 Radiotherapy 
Intensity modulated radiotherapy (IMRT) was delivered as previously described according to 
an institutional protocol [16, 20] using a compartmental approach to primary and lymph 
node levels was used for target volume delineation, to include the whole oropharynx and 
whole involved lymph node levels within the high dose volume. During this period outlining 
was performed by one of four radiation oncologists (outlining 15, 15, 12, 10 cases each).  
There were no formal prospective arrangements for contour peer review during this period 
although ad hoc informal review was commonly undertaken.  The standard dose was 70Gy 
in 35 fractions over 7 weeks.  The dose to the elective target volume was 57Gy in 35 
fractions with an intermediate dose level of 63Gy in 35 fractions available at clinician 
discretion.  Treatment was delivered using a 5-7 angle step and shoot technique. 
 
Statistics 
 
Descriptive statistics and correlations were performed using SPSS 24(Chicago, IL).  Follow up 
was calculated from the final date of radiotherapy.  The Shapiro-Wilk method was used to 
assess for normality in distribution (using a significance level at the 0.05 level) of the 
difference in composite MDADI scores on the first and second questionnaires (composite 
p=0.83, global p<0.01, emotional p=0.59, functional p=0.06, physical 0.07); parametric and 
non-parametric  tests were selected appropriately.  The paired t test was used to compare 
swallow function at both questionnaire time points for composite, emotional, functional 
and physical subscales; the Wilcoxon signed rank test was used for the global subscale. A 
difference in MDADI scores of t10 points was considered clinically significant [17].  In order 
to examine potential associations between patient/tumour/treatment factors, the 
composite MDADI  score was chosen as it reflects the overall performance [17].  The 
Shapiro-Wilk method was performed to assess normality of the composite summary score 
of the MDADA at each questionnaire timepoint and was non-significant (p=0.22 and p=0.29 
for first and second questionnaires respectively indicating a normal distribution).  Factors 
included in the analysis were: age, gender, T stage (T1/2 versus T3/4), use of prophylactic 
gastrostomy, use of enteral feeding during/shortly after treatment, pre-treatment swallow 
function (according to 5 point scale), mean contralateral parotid dose.  Smoking and alcohol 
consumption were not included as accurate information on long term follow up was not 
available.  ĞƉĞŶĚŝŶŐŽŶƚǇƉĞŽĨǀĂƌŝĂďůĞŝŶĚĞƉĞŶĚĞŶƚƚƚĞƐƚƐ ?WĞĂƌƐŽŶ ?ƐĐŽƌƌĞůĂƚŝŽŶ
ĐŽĞĨĨŝĐŝĞŶƚĂŶĚ^ƉĞĂƌŵĂŶ ?ƐƌŚŽǁĂƐƵƐĞĚƚŽĞǆĂŵŝŶĞĨĂĐƚŽƌƐƉŽƚĞŶƚŝĂůůǇĂƐƐŽĐŝĂƚĞĚǁŝƚŚ
swallowing outcomes as assessed by the composite summary MDADI score at each 
questionnaire timepoint.  ŶĞǆƉůŽƌĂƚŽƌǇĂŶĂůǇƐŝƐƵƐŝŶŐ^ƉĞĂƌŵĂŶ ?ƐĐŽƌƌĞůĂƚŝŽŶǁĂƐ
performed examining the same factors with a change of +/-10 points on the composite 
MDADI score. Correlations were considered significant at the 0.05 level (2-tailed).   
 
  
Results 
 
Patient and treatment characteristics for the 52 patients who had returned the first and 
second MDADI questionnaries are shown in Table 1. 27 (52%) had had a prophylactic 
gastrostomy inserted pre-chemoradiotherapy; the remaining patients were treated with the 
intention of management with a nasogastric tube as required.  Overall 41/52 (79%) of 
patients received enteral feeding support during chemoradiotherapy.  25/27 (93%) patients 
who had received a prophylactic gastrostomy received enteral feeding.  16/25 (64%) 
without a prophylactic gastrostomy received enteral feeding (14 via a nasogastric tube and 2 
via radiologically inserted gastrostomy following difficulties with nasogastric tube feeding).   
 
The first MDADI questionnaire was completed at a median of 34 months (range 24-59) post-
chemoradiotherapy.  The second MDADI questionnaire was requested after an interval of 30 
months from the initial questionnaire, at a median of 64 months (range 54-89) post-
treatment. 
 
2 (4%) patients were using a gastrostomy for enteral feeding at the time of the first MDADI 
questionnaire.  4 (8%) patients were using gastrostomy feed at the time of the second 
questionnaire.  2 of these 4 patients had documented osteoradionecrosis of the mandible.  
3 of 4 of these patients had a prophylactic gastrostomy and the remaining patient received 
NG feeding during treatment. 
 
Patient reported swallow function on long term follow up 
 
Patient reported swallow function as measured using the MDADI are shown in Table 2 and 
illustrated for the composite and global scores and each subdomain domain in Figure 1.  The 
distribution of changes in MDADI scores between the first and second questionnaires is 
illustrated in Figure 2.  Comparing MDADI scores at the two different timepoints, swallow 
function was significantly superior at the later timepoint for composite and global scores, 
and on emotional and functional domains, with a non-significant difference for the physical 
domain. However, as seen in Table 2, absolute differences in median scores between the 
two questionnaire timepoints were small. 
 A difference in MDADI of t10 points is considered clinically significant [17].  Table 3 
summarises how many patients had either a clinically significant deterioration or 
improvement or a difference of <10 points (stable) in their reported swallow function for 
the composite summary score and for each MDADI domain. In terms of the composite 
summary score, 29/52 (56%) of patients had stable swallow function over time with no 
clinically significant change.  6/52 (12%) and 17/52 (33%) patients had a clinically significant 
deterioration or improvement in swallow function respectively between the two 
questionnaires.  20/52 (38%), 20/52 (38%) and 28/52 (54%) of patients did not have a 
clinically significant change in emotional, functional and physical domains respectively. 
10 (19%), 12 (23%) and 15 (29%) experienced a clinically significant deterioration and 22 
(42%), 20 (38%) and 9 (17%) a clinically significant improvement in emotional, functional 
and physical domains respectively between the two MDADI questionnaires.  
 
Risk factors for swallowing function 
Potential associations between multiple clinical factors (age, sex, T stage, contralateral 
parotid dose, use of induction chemotherapy, number of concurrent chemotherapy cycles, 
pre-treatment diet, insertion of a prophylactic gastrostomy, enteral feeding during 
treatment (by any route))  and the  composite summary score of the MDADI were assessed 
(Table 4).  For the initial questionnaire (>2 years post-treatment) there was a significant but 
weak correlation with pre-ƚƌĞĂƚŵĞŶƚĚŝĞƚ ?ƉA? ? ? ? ? ? ?^ƉĞĂƌŵĂŶ ?ƐƌŚŽA? ? ? ? ? ? ?ƚ ?ǇĞĂƌƐƚŚĞ
composite summary MDADI score showed a significant association with pre-treatment diet 
(p=0.029, rho 0.33) and with the insertion of a prophylactic gastrostomy with a mean 
MDADI for patients who received a prophylactic gastrostomy of 63.0 (SD 11.2) versus 73.8 
(SD 19.3) for those who did not (p=0.044) An exploratory analysis did not demonstrate any 
correlations between the same factors and a clinically significant improvement or 
deterioration of r10 points between the composite MDADI scores (all p values >0.3); 
however these results should be interpreted with caution in view of the exploratory nature 
of the analysis. 
 
  
Discussion 
 
Late dysphagia is increasingly recognised as an important long term morbidity of 
chemoradiotherapy.  Survivorship issues have become particularly important in the  
era of human papilloma virus (HPV)-related oropharyngeal carcinoma with a more 
favourable prognosis and many patients are living for many years with the long term 
sequalae of treatment .   There is a paucity of data available to determine the impact of 
dysphagia upon patients >2 years post-treatment, and very little information available 
regarding how dysphagia may change over many years post treatment.  We [10, 16] and 
others [21] have previously evaluated swallow function using the MDADI at least 2 years 
post-treatment on the basis that it is likely to be stable and reflect long term outcomes after 
this length of time post-treatment.  However, it may be hypothesised that progressive 
radiotherapy fibrosis and superimposed age-related changes [13] may cause a progressive 
deterioration in swallow function.  Conversely, compensatory adaptation may lead to an 
improvement in swallow related QoL [13].   
 
The assessment of swallow outcomes is complex with a host of potential tools, including 
physician assessed toxicity scores, physical outcomes including videofluoroscopy and 
multiple patient reported measure [1].  It has been shown that these do not necessarily 
correlate, with data suggesting that patients may rate dysphagia more severely [13, 22, 23].  
Therefore, patient reported outcome measures are key tools in assessment of dysphagia.   
The MDADI is a well used, reliable and validated patient reported outcome measure [15, 
17]. 
 
In this study 52 patients had completed the MDADI at two different timepoints at least 2 
and 5 years post-chemoradiotherapy and separated an interval of 30 months for each 
patient.  These data therefore provide the opportunity to evaluate the impact of extended 
time post-treatment upon dysphagia.  Overall changes in median MDADI scores were small 
(Table 2) although there was a statistically significant improvement in MDADI scores overall, 
and in the global, emotional and functional domains, with non-significant improvement in 
the physical domain (Table 2, Figure 1); these small changes are of debatable clinical 
significance overall.  However, such summary measures conceal the experience of individual 
patients.  Using a change in MDADI score of t10 as being clinically significant [17], the data 
shown in Table 3 reveals that swallow function was stable with time in the majority of 
patients (composite MDADI change <10 points in 29/52 (56%) of patients.  Overall 33% of 
patients report an improvement in swallow function based upon composite scores (42%, 
38%, 17% improve in emotional, functional and physical subscales).  By contrast, overall 12% 
of patients report a deterioration in swallow function (19%, 23%, 29% deteriorate in 
emotional, functional and physical subscales).  Therefore, these data suggest that dysphagia 
can be a dynamic process, with stable function in the majority in the long term, with a 
subset of patients improving and another subset of patients deteriorating.  No patient, 
tumour or treatment related factors were identified which correlated with an improvement 
or deterioration in swallow function between the two questionnaire timepoints.   
 
A prior study by Frowen et al. [13] has also informed on changes in swallow function over 
long term follow up using paired data at 6 months and 5 years post-treatment in a series of 
39 patients using the swallowing scale of the Australian Therapy Outcome Measures 
(AusTOMs) relating to patient reported swallowing activity along with the MDADI and 
videofluroscopy in a subset 21 of these patients.  This study found that patient-reported 
swallowing activity for solids, but not liquids, significantly improved for all patients between 
6 months and 5 years.  However, the semi-solid swallowing measure deteriorated over time, 
with a significant difference between 6 months and 5 years post treatment. In the 
videofluroscopy, pharyngeal residue significantly increased between 6 months and 5 years 
post treatment (19% versus 31%).   One important finding of this study is the discrepancy 
between swallow dysfunction on videofluoroscopy which was either stable or deteriorated 
whilst patient-reported activity which improved.  The authors considered that this may 
relate to patient adaptation over time. 
 
By contrast with our data and that of Frowen et al. [13] suggesting a time dependence to 
the severity of dysphagia, a retrospective study of 83 patients evaluated using the Sydney 
Swallow Questionnaire at a mean of 3 years (range 0.5-8) post-treatment found a 
prevalence of dysphagia of 59% and that severity was not predicted by time from therapy 
[14].   
 
Some [16, 21, 24], but not all [25], prior studies have suggested that the use of a 
prophylactic gastrostomy may be detrimental to long term swallow function.  In our centre 
the decision to place a prophylactic gastrostomy was based upon clinician and patient 
preference ie. patients commonly offered a choice.  In this cohort 52% of patients had a 
prophylactic gastrostomy placed.  We have previously reported a matched pair analysis 
performed to account for confounding factors based upon the first MDADI questionnaire 
timepoint [16] finding significantly inferior MDADI scores in the group with a prophylactic 
gastrostomy.  Although that matched pair analysis did not include all of the patients 
reported here, a correlation between the insertion of a prophylactic gastrostomy and 
inferior MDADI scores was seen here on the second MDADI questionnaire >5 years post-
treatment.  As previously discussed [16], there are potential confounding factors which may 
influence this correlation and this observation is hypothesis generating.  Consistent with 
other data that acute dysphagia requiring enteral tube feeding is not related to risks of long 
term dysphagia [26], the use of enteral feeding during treatment did not correlate with 
MDADI scores at either timepoint.   
 
Limitations of this study include the variable timepoints post-treatment at which patients 
completed the first and second MDADI questionnaires. However, these were a minimum of 
2 and 4 ½ years post-treatment respectively with a fixed interval of 30 months between 
administration of questionnaires. Swallow function was assessed only by the MDADI; 
although patient reported outcomes are key outcome measures, it is not possible to 
determine from these data how swallow function based on objective assessment (eg. 
videofluoroscopy) compares.  The patients in this study were treated in the early days of 
IMRT within our institute; the mean contralateral parotid dose is higher than would 
currently be expected and the compartmental approach of including the whole oropharynx 
within the high dose target volume is no longer our standard of care.  It is possible that 
these factors may negatively impact upon long term swallow function. Dose to the 
pharyngeal constrictor muscles is recognised as a factor in long term swallow function [1,27] 
and pharyngeal constrictor organs at risk were not outlined.  The approach of including the 
whole oropharynx as a high dose compartment does not allow for pharyngeal constrictor 
sparing.  Although it is possible that there may have been inter-clinician variability in 
outlining, with a lack of formal contour peer review in this era, it is therefore unlikely that 
this would have impacted upon dose to pharyngeal constrictors and hence swallow 
outcomes.    In addition, HPV data is not available for this historical cohort of patients; 
however, there is no data to suggest that HPV-status would impact upon treatment-related 
long term dysphagia rates.  23% of patients received induction chemotherapy in this era; 
this is no longer our standard approach. 
 
In summary, this study shows that long term dysphagia continues to have an impact upon 
patients many years following chemoradiotherapy, and is a major survivorship issue.  Long 
term dysphagia is not a static process.  Based upon composite MDADI scores, long term 
swallow function was stable in 56% of patients, whilst 33% experienced an improvement, 
and 12% of patients experienced continued deterioration in swallow function over many 
years follow up.  No factors were identified which predicted which patients may improve or 
deteriorate.  Further evaluation of these patients having divergent outcomes is important to 
determine the underlying mechanisms and to guide potential therapeutic interventions. 
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Figure Legends 
 
Figure 1: Patient reported outcomes from MDADI in long term. 52 patients with 
oropharyngeal carcinoma completed MDADI at first timepoint at median 34 months post-
chemoradiotherapy (dark grey) and at second timepoint 30 months later (median 64 
months post-chemoradiotherapy) (light grey). A=composite score. B=global score. 
C=emotional domain.  D=functional domain. E=physical domain.  Count=number of patients. 
 
 
Figure 2: Summary of changes in MDADI scores between first and second questionnaires.  
Boxplots:  A=composite score, B= global score, C=emotional domain, D=functional domain, 
E=physical domain.  Paired t test used when difference between scores was normally 
distributed (composite, emotional, functional, physical scales).  Wilcoxon signed rank test 
used when difference between scores not normally distributed (global).  Note emotional, 
functional and physical questionnaires contain questions also contained within the 
composite score.  Therefore caution is required in interpretation of statistical significance of 
overlapping data. 
